Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
July 02 2018 - 4:30PM
Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced the closing of its
previously announced underwritten public offering of common stock,
including the exercise in full by the underwriters of their option
to purchase an additional 600,000 shares at the public offering
price of $16.75 per share. The exercise of the option to purchase
additional shares brought the total number of shares of common
stock sold by Kura Oncology to 4,600,000 shares and increased the
amount of gross proceeds raised in the offering, before
underwriting discounts and estimated expenses of the offering
payable by Kura Oncology, to approximately $77.1 million.
Leerink Partners acted as sole book-running manager for the
offering.
The securities described above were offered by Kura Oncology
pursuant to effective registration statements on Form S-3,
including a base prospectus, that were previously filed by Kura
Oncology with the Securities and Exchange Commission (the “SEC”). A
final prospectus supplement and the accompanying prospectus
relating to the offering have been filed with the SEC and are
available for free on the SEC’s website located at
http://www.sec.gov. Copies of the final prospectus supplement and
the accompanying prospectus relating to the offering may be
obtained from Leerink Partners LLC, Attention: Syndicate
Department, One Federal Street, 37th Floor, Boston, MA 02110, or by
telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@leerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. Kura Oncology’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura Oncology’s lead drug candidate is
tipifarnib, a farnesyl transferase inhibitor, which is currently
being studied in multiple Phase 2 clinical trials in solid tumor
and hematologic indications. Kura Oncology’s pipeline also includes
KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation
trial, and KO-539, a menin-MLL inhibitor, currently in preclinical
development.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as “believes,” “anticipates,” “plans,” “expects,” “intends,”
“will,” “goal,” “potential” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Kura Oncology’s current expectations and
involve assumptions that may never materialize, or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
risks and uncertainties associated with Kura Oncology’s business
and finances in general, and the other risks described in Kura
Oncology’s quarterly report on Form 10-Q for the quarterly period
ended March 31, 2018, and other filings with the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Kura Oncology
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke Partners,
LLC(858) 356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024